5-氟尿嘧啶5%乳膏治疗原位鳞状细胞癌:影响治疗反应的因素
本研究回顾性分析了149例活检证实的原发性原位鳞状细胞癌(SCCis)患者,均接受5-氟尿嘧啶(5-FU)5%乳膏治疗。结果显示,较短的疗程和较大的肿瘤尺寸与治疗失败显著相关,而免疫抑制状态和解剖部位并非显著因素。
要点
- 免疫抑制状态和解剖部位不影响5-FU治疗SCCis的失败率。
核心结论
- 较短治疗疗程和较大病灶尺寸与5-FU治疗原位鳞状细胞癌失败显著相关。
- 免疫抑制和解剖部位不是显著影响因素,支持在免疫抑制人群中使用5-FU。
研究设计与样本
- 回顾性研究,纳入2019年5月1日至2020年4月30日活检证实的原发性SCCis病例,共149例,均接受5-FU 5%乳膏治疗。
关键数值与推荐
- 完全临床缓解率总体范围为27%至85%(原文背景)。
临床怎么用
- 对于SCCis,使用5-FU 5%乳膏时应确保足够疗程(≥4周可能更优),尤其对较大病灶需考虑治疗失败风险。
- 免疫抑制患者和解剖部位不影响疗效,可考虑使用5-FU治疗。
局限性
- 回顾性研究设计可能存在选择偏倚和信息偏倚。
- 样本量有限,尤其某些亚组(如肿瘤≥2 cm仅5例)样本量小。
- 未报告其他潜在混杂因素的控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Complete clinical response (CCR) rates for squamous cell carcinoma in situ (SCCis) treated with 5-fluorouracil (5-FU) 5% cream range from 27% to 85%. Factors associated with CCR are not well-established. METHODS: Retrospective review of biopsy-proven primary SCCis diagnosed between May 1, 2019, and April 30, 2020, and treated with 5-FU 5% cream. Disease status at follow-up was recorded, with treatment failure defined as persistent or recurrent disease. RESULTS: The study included 149 SCCis cases, including 33.6% (50/149) arising in the context of immunosuppression. Eighteen cases failed treatment (10 persistent disease, 8 recurrent disease). By tumor size, CCR was noted in 128/144 (88.9%) tumors measuring <2 centimeters in diameter and 3/5 tumors ≥2 centimeters (60.0%, P = .051). By treatment duration, CCR was observed in 4/7 (57.1%) tumors treated for <2 weeks, 72/83 (86.7%) tumors treated for 2 to <4 weeks, and 55/59 (93.2%) tumors treated for ≥4 weeks (P = .019). On multivariate analysis, treatment failure was significantly associated with shorter treatment durations (odds ratio: 0.26; P = .007) and increasing tumor size (odds ratio: 2.40; P = .037). CONCLUSIONS: Shorter treatment duration and larger lesion size were significantly associated with failure of 5-FU in SCCis. Immunosuppression and anatomic location were not significant factors, supporting 5-FU use for SCCis in the immunosuppressed population and highlighting its versatility irrespective of anatomic location.
引用
- Lin CP, Kibbi N, Bandali T, et al. 5-fluorouracil 5% cream for squamous cell carcinoma in situ: Factors impacting treatment response. J Am Acad Dermatol. 2024. PMID: 39521136. doi:10.1016/j.jaad.2024.10.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。